ERBB2 and prostate cancer: Precedence for activated and targetable, N-terminally truncated tyrosine kinases has been reported for HER2 44–46, ALK47, c-KIT48, and EGFR49 which lack the extracellular and transmembrane regions in breast, melanoma, prostate cancers, and gliomas, respectively.